Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
06 nov. 2023 16h01 HE
|
Voyager Therapeutics, Inc.
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development...
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
30 oct. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
25 sept. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 sept. 2023 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
30 août 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 août 2023 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
07 août 2023 08h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
03 août 2023 07h00 HE
|
Voyager Therapeutics, Inc.
- Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - -...
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
02 août 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
27 juil. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...